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SUMMARY
Patientswith ALS show, in addition to the loss ofmotor neurons in the spinal cord,
brainstem, and cerebral cortex, an abnormal depletion of energy stores along-
side hypermetabolism. In this study, we show that bioenergetic defects and mus-
cle remodeling occur in skeletal muscle of the SOD1G93A mouse model of ALS
mice prior to disease onset and before the activation of muscle denervation
markers, respectively. These changes in muscle physiology were followed by an
increase in energy expenditure unrelated to physical activity. Finally, chronic
treatment of SOD1G93A mice with Ranolazine, an FDA-approved inhibitor of fatty
acid b-oxidation, led to a decrease in energy expenditure in symptomatic
SOD1G93A mice, and this occurred in parallel with a robust, albeit temporary, re-
covery of the pathological phenotype.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is characterized by the progressive loss of upper and lower motor neu-
rons. The loss of these neurons leads to the concomitant development of skeletal muscle atrophy (Rossi
et al., 2015). ALS is a disease of obscure etiology, for which neither a cure nor a therapeutic option is avail-
able. ALS is a multifactorial disease and a number of mechanisms have been proposed to underpin disease
pathology, including alterations in RNA metabolism, oxidative stress, axonal transport defects, neuroin-
flammation, impaired protein homeostasis, alterations in autophagic flux, aberrant cytoplasmic-nuclear
shuttling, failure in DNA repair, excitotoxicity, mitochondrial dysfunction, and vesicular transport defects
(Mejzini et al., 2019).
In spite of its elusive etiology, some well-described clinical signs in patients with ALS highlight
promising lines of investigation to improve our understanding of disease. Notably, hypermetabo-
lism (Steyn et al., 2018) and weight loss (Moglia et al., 2019) are associated with worse prognosis.
However, weight loss, undernutrition, muscle atrophy, weakness, and reduced physical activity
(Ioannides et al., 2016) appear incompatible with clinical studies reporting increased energy expen-
diture (EE) in patients with ALS (Bouteloup et al., 2009; Desport et al., 2005; Funalot et al., 2009;
Kasarskis et al., 2014). The paradox may be reconciled by assuming that skeletal muscle plays a
pathological role in ALS, contributing to defective energy metabolism and a derangement of basal
metabolic rate. Indeed, skeletal muscle is a key determinant of whole-body metabolic rate (Zurlo
et al., 1990).
In this context, the early events underlying defective muscle metabolism in ALS as well as the major molec-
ular mechanisms that cause ALS-associated hypermetabolism are still unknown. We therefore undertook
this investigation to provide insights into the early pathological events involved in ALS by examining the
mechanisms responsible for maladaptive muscle oxidative metabolism and disease progression. Finally,
in this study, we provided evidences to show that pharmacological modulation of metabolism can curtail
excessive EE and improve ALS pathology, thereby demonstrating that limiting hypermetabolism could be
a promising therapeutic target in ALS.
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RESULTS
An Increase in Fatty Acid Oxidation and Glucose Intolerance Precedes Hypermetabolism in
SOD1G93A Mice
To investigate the whole-body metabolic status and fuel oxidation in SOD1G93A mice, we conducted indi-
rect calorimetry over 2 or 3 continuous days. Measures were obtained from animals at the early presymp-
tomatic (55 days of age) and symptomatic (120 days of age) stages of disease. Hypermetabolism, defined as
an increase in total EE or resting energy expenditure (REE), was not detectable in early presymptomatic
mice (Figures 1A–1C) but was strongly evident in symptomatic mice (Figures 1D–1F). Analysis of the respi-
ratory exchange ratio (RER) revealed a significant genotype effect, with RER being reduced in both early
presymptomatic and symptomatic SOD1G93A mice when compared with wild-type control mice (Figures
1G and 1H). These results are indicative of enhanced fatty acid oxidation and predominant use of fatty acids
as fuel source in ALS mice.
After confirmed metabolic alteration in presymptomatic SOD1G93A mice and since skeletal muscle is the
major factor affecting EE also at rest (Zurlo et al., 1990) we carried out RNA sequencing to assay gene
expression changes in the tibialis anterior (TA) of SOD1G93A mice at the onset stage of disease, when
compared with their wild-type littermate controls. Gene enrichment analysis, using Reactome categories,
highlighted that the gene sets most significantly enriched among downregulated genes were associated
with glucose metabolism (Figure 1I). In particular, we observed downregulation of key glycolysis pathway
genes (Figures 1J and 1K). The decrease in the expression of glycolytic pathway genes was further sup-
ported through our assessment of glucose tolerance in SOD1G93A mice. At the early presymptomatic stage,
SOD1G93A mice already show a marked decrease in blood glucose clearance with respect to wild-type con-
trol littermates (Figure 1L, upper panel). This metabolic alteration dramatically worsened with disease pro-
gression in SOD1G93A mice (Figure 1L, middle and lower panels).
ALS Skeletal Muscles Undergo Metabolic Reprogramming
Based on results obtained through indirect calorimetry and transcriptome analysis, we aimed to define the
timing of the onset of metabolic changes in skeletal muscle of SOD1G93A mice by analyzing the oxidative
capacity of the glycolytic TA at different time points. We found that in situ NADH-TR and SDH activities
were dramatically increased in SOD1G93A mice at the early presymptomatic stage (55 days) and to a higher
degree at the later stages of the disease (Figures 2A, 2B, S1A, and S1B).
In line with the rise inmuscle oxidative capacity, we detected, by immunofluorescence analysis, a consistent
increase in the intensity of ATPB, a known mitochondrial marker, in the TA muscle of SOD1G93A mice (Fig-
ures 2C and S1C). Accordingly, a striking increase in mitochondrial mass was observed, defined by an in-
crease in the amount (mg) of mitochondria per milligram of tissue as well as an increase in the content of
mitochondrial DNA, in different muscles of SOD1G93A mice during the course of the disease (Figures
S2A–S2C). Interestingly, this phenomenon occurred mainly in glycolytic muscles and not in the oxidative
soleus muscle.
The switching of skeletal muscle metabolism toward an oxidative phenotype in SOD1G93A mice was further
corroborated by the upregulation in neuron-derived orphan nuclear receptor (Nor1) mRNA in the TA (Fig-
ure 2D). This transcription factor is known to promote muscle remodeling toward oxidative metabolism by
activating pathways critical for adaptation to exercise or energy deficit (Goode et al., 2016). The upregula-
tion of Nor1 in SOD1G93A mice occurred alongside an upregulation in mRNA encoding for myoglobin (Fig-
ure 2D) (Pearen et al., 2013). Moreover, we found significant alterations in the expression of mRNAs encod-
ing myosin heavy chain isoforms. Specifically, we observed a reduction in the expression of the glycolytic
isoform MyCHIIb and an increase in the expression of the oxidative/intermediate isoforms MyHCIIa and
MyHCIIx (Figure 2E). No significant alterations were observed in the expression of the oxidative isoform
MyHCI (Figure 2E). Overall, these data show that, in SOD1G93A mice, glycolytic muscles undergo a pro-
found rearrangement in their physiology throughout the course of disease.
Mitochondrial Bioenergetics Are Perturbed in Skeletal Muscle of Early Presymptomatic
SOD1G93A Mice
The metabolic modifications of skeletal muscle observed in SOD1G93A animals mirror adaptations to
endurance training, wherein a switch from glycolytic to oxidative metabolism occurs (Granata et al.,
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2018; Widmann et al., 2019). During endurance training, this metabolic switch is accompanied by an in-
crease in mitochondrial mass alongside significant remodeling of myofibers and a preferential use of fatty
acids as fuel (Granata et al., 2018; Widmann et al., 2019). Although we found that mitochondrial mass in
glycolytic TA muscle of SOD1G93A mice increased during the disease course, we also noted an early mito-
chondrial bioenergetic defect. In this regard, we found that total ATP was significantly lower in the TA of
SOD1G93A mice at the early symptomatic through to the mid-stage of disease when compared with age-
matched wild-type control mice (Figure 3A). Moreover, we observed a marked reduction in all mitochon-
drial functionalities in the TA of SOD1G93A mice at the early presymptomatic phase of the disease. Similarly,
early reductions in mitochondrial function were also observed in other glycolytic muscles, gastrocnemius
(GNM) and extensor digitorum longus (EDL) (Figures S3A and S3B). Interestingly, bioenergetic defects
only become detectable in the spinal cord at onset of the pathology (Figures 3C and S3B).
To further investigate the mitochondrial bioenergetic deficit in SOD1G93A mice, we assessed respira-
tion states of mitochondria isolated from skeletal muscle and spinal cord of SOD1G93A mice and
wild-type litter matched controls. We observed a decrease in maximally coupled respiration (state
2), thereby confirming the impairment in ATP production. Moreover, maximal respiration (state 4),
determined through the addition of the uncoupling agent FCCP, appeared to be significantly compro-
mised in mitochondria obtained from glycolytic TA, GNM, and EDL of presymptomatic SOD1G93A mice
(Figures 3B, S3A, and S3B). Interestingly, mitochondria purified from a purely oxidative muscle, the so-
leus, were not affected (Figures S3A and S3B). With the aim of characterizing the alterations in the
electron transport chain, we performed a spectrophotometric analysis of the functional activities of
the mitochondrial complexes and observed a specific impairment in Complex I in mitochondria puri-
fied from the TA (Figure 3D) and GNM (not shown) of early presymptomatic SOD1G93A mice. Again,
this dysfunction was evident in skeletal muscle from early presymptomatic SOD1G93A mice, whereas
defects in Complex I activity were only observed in the spinal cords of SOD1G93A mice at the symp-
tomatic and end stage of disease (Figure 3E).
Next, we performed Blue Native polyacrylamide gel electrophoresis (BN-PAGE) analysis of digitonin-
extracted mitochondrial membranes obtained from the TA of SOD1G93A mice and their wild-type con-
trol littermates at different ages (Figure S3C). We found no difference in the assembly of electron
transport chain complexes or supercomplexes in mitochondria obtained from SOD1G93A mice when
compared with age-matched controls. Finally, bioenergetic assessment of primary cultures of skeletal
muscle satellite cells isolated from early presymptomatic SOD1G93A mice (55 days of age) revealed sig-
nificant decreases in basal respiration, ATP production, maximal respiration, and spare respiratory ca-
pacity when compared with those isolated from their wild-type control littermates (Figures 4A and 4B).
The decline in maximal respiration and spare respiratory capacity suggests that ALS may inhibit the
rapid adaptation of skeletal muscle satellite cells to metabolic changes. Thus, although the number
of mitochondria in the whole muscle appears to increase in SOD1G93A mice, mitochondrial metabolism
is compromised early in the course of the disease, leading to ATP deficit and impairments in OXPHOS
functionality.
Muscle Mitochondrial Deficit in SOD1G93A Mice Occurs in Parallel with an Activation of
Molecular Pathways that Compensate for Energy Failure
In normal physiology, a decrease in ATP production (mitochondrial alterations) leads to an enhancement in
AMPK activity to promote the binding of AMP (and ADP) to the kinase subunit. This in turn induces the
phosphorylation of a wide range of downstream proteins that eventually lead to the activation of catabolic
pathways (Hardie et al., 2016). In particular, pharmacological or genetic inhibition of Complex I is sufficient
to activate AMPK (Hardie et al., 2016; Thomas et al., 2018). Therefore, in light of the bioenergetic defects
Figure 1. Energy Expenditure and Metabolic Profile of WT and SOD1G93A Mice
(A–L) (A) Energy expenditure profiles of early presymptomatic SOD1G93A mice (55 days) and their wild-type control littermates (WT). Black bar indicates dark
cycle period. Mean (B) energy expenditure (EE) and (C) resting energy expenditure (REE) calculated from (A). (D) Energy expenditure profiles of symptomatic
SOD1G93A mice (120 days) and their wild-type control littermates (WT). Mean (E) EE and (F) REE calculated from (D). (G and H) Mean RER from (A) and (D),
respectively. (I) Gene expression changes in the tibialis anterior (TA) muscle from SOD1G93A mice and their wild-type control littermates. (J) Heatmap
depicting expression of genes from the Reactome category ‘‘Glycolysis.’’ Shown genes are differentially expressed with adjusted p < 0.05. (K) Network plot
of the "Pyruvate metabolism and Citric Acid (TCA) cycle" pathways. Nodes are genes colored based on log2FC, edges are knowledge-based interactions
annotated by Reactome. (L) Glucose tolerance test performed in SOD1G93A and in their wild-type control littermates (WT) at 55, 90, and 120 days of age,
respectively. Data in (B), (C), (E), (F), (G), and (H) are presented as mean G SEM, ***p < 0.0001, unpaired Student’s t test.
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Figure 2. Muscle Metabolism Switches from Glycolytic to Oxidative in SOD1G93A Mice
(A) Representative NADH-tetrazolium reductase activity staining on tibialis anterior (TA) cross sections obtained from 55-, 90-, and 150-day-old SOD1G93A
mice and their wild-type control littermates (WT). Scale bar, 100 mm, n = 3.
(B) Representative SDH activity staining on TA cross sections of 55-, 70-, 90-, and 120-day-old SOD1G93A mice and their wild-type control littermates (WT).
The darker color indicates the site of SDH activity. Scale bar, 100 mm, n = 3.
(C–E) (C) Representative images of TA sections from 55-, 90-, and 150-day-old SOD1G93A and wild-type (WT) mice, immunostained with laminin (green) and
the mitochondrial marker ATPB (red); nuclei were detected with Hoechst 33342 (blue). Scale bar, 100 mm, n = 3. Expression level of mRNAs coding for (D)
Nor1 andMyoglobin and (E) MyHCI, MyHCIIa, MyHCIIIx, andMyHCIIb in TA sections obtained from SOD1G93A at the indicated ages (at least n = 4). Data are
presented as meanG SEM, *p < 0.05, **p < 0.001, ***p < 0.0001, compared with wild-type control littermates at the same age (arbitrarily set at 1), unpaired
Student’s t test.
Also see Figures S1A–S1C.
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observed in early presymptomatic mice and the specific impairment of Complex I activity, we analyzed the
extent of AMPK activation in ALS mice.
Glycolytic skeletal muscles from SOD1G93A mice displayed a robust activation of AMPK, long before the
appearance of locomotor symptoms (Figures 5A and S4). AMPK activation occurred in parallel with the
phosphorylation/inactivation of the AMPK downstream target Acetyl-CoA Carboxylase (ACC), which cat-
alyzes the first step of fatty acid synthesis (Figures 5A and S4). Moreover, we found an upregulation in carni-
tine palmitoyltransferase 1 (CPT1) in the skeletal muscle of presymptomatic SOD1G93A mice (Figures 5A
Figure 3. Mitochondrial Bioenergetic Failure Occurs in Skeletal Muscle of Early Presymptomatic SOD1G93A Mice
(A) Fluorometric measurements of total ATP in the tibialis anterior (TA) muscle from SOD1G93A and wild-type age-
matched control mice (WT) at different ages. Data were analyzed by unpaired t test and presented as mean G SEM,
***p < 0.0001 compared with age-matched WT mice (n = 4 independent experiments).
(B) Coupling assay on isolated mitochondria purified from TA.
(C) Spinal Cord of SOD1G93A mice at the indicated ages. Mitochondrial respiration stages are reported as basal
respiration (state 2), maximal coupled respiration (state 3), respiration due to proton leak (state 4o), and maximal
uncoupled respiration (state 3u). Data are expressed as % Oxygen Consumption Rate (OCR), and 100% was arbitrarily
assigned to values obtained from age-matched wild-type mice, *p < 0.05, **p < 0.001, ***p < 0.0001, unpaired Student’s
t test (n = 5 independent experiments).
(D) Activity of electron transport chain complexes I, II\III, and IV of mitochondria obtained from TA.
(E) Spinal Cord of SOD1G93A and wild-type (WT) mice at the indicated ages. Values were normalized to citrate synthase
activity and presented as meanG SEM, **p < 0.001, ***p < 0.0001 compared with age-matchedWTmice (arbitrarily set at
100%), unpaired Student’s t test (n = 5 independent experiments).
Also see Figures S2A–S2C and S3A–S3C.
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and S4). Finally, in support of a metabolic shift toward lipid use, we observed a decrease in the expression
of Glucose Transporter type 4 (Glut4) mRNA and the concomitant increase in pyruvate dehydrogenase ki-
nase 4 (Pdk4) mRNA in skeletal muscle of presymptomatic mice (Figure 5B).
Sarcolipin Is an Early Player in ALS Metabolic Alterations
Recent studies have outlined the pivotal role of sarcolipin (SLN) in orchestrating the transition toward
oxidative metabolism in skeletal muscle (Maurya et al., 2018). In line with the literature (Babu et al.,
2007), we found that SLN is highly expressed in the TA of wild-type control mice until 14 days of age, after
which it gradually declines (Figure 6A). By contrast, in SOD1G93A mice, the expression level of SLN re-
mained detectable in TA beyond 14 days of age, increasing during the course of the disease (Figure 6A).
Indeed, in SOD1G93A mice, SLN overexpression was strongly upregulated through to the end stage of dis-
ease in all glycolytic and oxidative muscles assessed. This is in contrast to the expression profile of SLN in
Figure 4. Mitochondrial Bioenergetics Failure Occurs in Skeletal Muscle Satellite Cells Isolated from Early
Presymptomatic SOD1G93A Mice
(A) Representative trace of oxygen consumption rate (OCR) in skeletal muscle satellite cells isolated from early
presymptomatic SOD1G93A mice (55 days) and their wild-type control littermates (WT).
(B) Individual parameters obtained for basal respiration, ATP production, maximal respiration, and spare respiratory
capacity. Each data point represents an OCR measurement. Data are presented as mean G SEM, **p < 0.001, ***p <
0.0001 relative to WT control, p values obtained from unpaired Student’s t test. Data from four independent experiments,
with each sample tested in quadruplicate.
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age-matched wild-type control mice, where SLN was only detectable in the oxidative soleus (Figure 6B). Of
note, we did not observe any significant variation in mRNA expression of phospholamban (PLN) or myor-
egulin (MLN) (Figure S5A), muscular micropeptides that function similarly to SLN. Thus, our data suggest
that SLN is the only SERCA-regulatory micropeptide involved in ALS.
Figure 5. Alterations in Expression of Metabolic Targets Occurs Early in the tibialis anterior (TA) of SOD1G93A
Mice
(A) Representative western blot images of pAMPK, AMPK, pACC, ACC, and CPT1 (upper panel) in the TA of SOD1G93A
and wild-type mice at 55 days of age. GAPDH was used as loading control. Densitometric analysis of pAMPK/AMPK and
pACC/ACC ratios and CPT1 expression (lower panel) from n = 4 independent experiments.
(B) Expression of mRNAs coding for Pdk4 and Glut4 in the TA of SOD1G93A mice relative to wild-type litter-matched
controls. Data presented as meanG SEM, *p < 0.05, **p < 0.001, ***p < 0.0001 when compared with control littermates at
the same age (arbitrarily set at 1), unpaired Student’s t test.
Also see Figures S4 and S5A–S5C.
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An upregulation in SLN is known to trigger an increase in cytosolic calcium concentration in skeletal muscle
(Maurya and Periasamy, 2015). To this end, we found a significant activation of Ca2+/calmodulin-dependent
protein kinase II (CaMKII) in skeletal muscle of SOD1G93A at the presymptomatic stage of the disease, when
the glycolytic muscle was highly oxidative (Figure 6C). Moreover, we observed a significant increase in
PGC-1a protein expression in the TA of SOD1G93A mice at the presymptomatic phase of disease
(70 days of age) as well as throughout the course of the disease (Figure S5B).
The expression pattern of mRNAs coding for different isoforms of SERCA pumps reflects the metabolic
profile of muscle. SERCA2a and SERCA2b isoforms that are normally associated with oxidative muscle,
were more highly expressed in the TA from SOD1G93A mice, whereas the glycolytic muscle-associated
SERCA1 isoform was downregulated at the presymptomatic stage (Figure S5C). It is noteworthy that
SLN selectively binds SERCA2 isoforms, interacting with these to trigger the transition of skeletal muscle
from glycolytic to oxidative metabolism (Anderson et al., 2016). Finally, highly relevant was the finding
that SLN expression was upregulated in muscle biopsies obtained from six patients affected by different
forms of ALS (for details see Table 1). Indeed, all ALS biopsies showed higher expression levels of SLN
when compared with control patients affected by other muscular disorders (Figures 6D and 6E).
Sarcolipin Overexpression in SOD1G93A Mice Is Not Related to Muscle Denervation
Several pathological conditions that lead to skeletal muscle disuse and subsequent atrophy affect not only
muscle mass but also muscle metabolism (Tintignac et al., 2015). SLN has been described to be a key medi-
ator of metabolic modifications occurring in unloaded/disused muscle (Fajardo et al., 2017). Thus, to
discriminate whether SLN upregulation is causally linked to the altered metabolic state observed in ALS
mice, or whether it is merely a consequence of early denervation, we analyzed the expression levels of
several denervation/atrophy markers. Our results demonstrate that, in TA from SOD1G93A mice, SLN is up-
regulated at the early presymptomatic stage, whereas mRNAs coding for Hdac4, Nav1.5, Myogenin,
AchRε, AchRa, Murf1, and Myostatin, all associated with the denervation process, are only increased at
the later stages of disease (Figure 6F).
In order to further decipher the relationship between denervation and metabolic alterations in skeletal
muscle from ALS mice, we used an experimental paradigm of acute denervation. As shown in Figure 6G,
sciatic nerve axotomy in control mice evoked an upregulation in denervation markers after 3 days, whereas
SLN was only found to increase after 15 days. Overall, our data strongly suggest that, in ALS, muscle meta-
bolic reprogramming is orchestrated by SLN and this occurs independent of denervation.
Altered Muscle Performance in SOD1G93A Mice Is Related to Hypermetabolism
Given the altered bioenergetic profiles observed in SOD1G93A mice, we next tested whether pharmacolog-
ical targeting of altered energy metabolism could be a beneficial therapeutic approach in ALS. To address
this aim, we chronically administered ranolazine (RAN) to SOD1G93A mice. RAN is a US Food and Drug
Administration (FDA)-approved drug that is used to treat ventricular hypertrophy, and it has been shown
to exert cardioprotective effects by facilitating higher energy production under conditions of lower oxygen
Figure 6. Upregulation of Sarcolipin in ALS Occurs before Denervation in SOD1G93A Mice
(A and B) Representative western blots of sarcolipin (SLN) protein expression in the (A) tibialis anterior (TA) or (B) Extensor digitorum longus (EDL),
gastrocnemius (GNM), and soleus muscle of SOD1G93A (+) and wild-type mice () at the indicated ages.
(C) Western blot of pCaMKII and CaMKII in the TA of SOD1G93A (+) and wild typemice () at the indicated ages; GAPDHwas used as loading control in (A–C).
(D) SLN protein expression in different muscle biopsies derived from MELAS, neuropathy (N), not Limb Girdle Muscle Dystrophy (LGMD) and patients with
ALS (1 = SOD1D90A mutation, soleus; 2 = sporadic, vastus lateralis; 3 = Valosin Containing Protein (VCP) mutation, vastus lateralis; 4 = C9ORF72 repeat
expansions, soleus; 5 = sporadic, vastus lateralis; 6 = sporadic, rectus femoralis).
(E) Densitometric analysis of (D) normalized to GAPDH protein expression. Data are presented as a percentage, where an arbitrary value of 100% was
assigned to patients with ALS, ***p < 0.0001, one-way parametric ANOVA and Tukey’s post hoc test.
(F) Expression of mRNAs coding for Sarcolipin (Sln), Acetylcholine Receptor a subunit (Achra), Acetylcholine Receptor e subunit (Achre), Voltage-gated Na
channels 1.5 (Nav1.5), Histone Deacetylase 4 (Hdac4), Myogenin, MuscleRING Finger-1 (Murf1), and Myostatin in the TA of SOD1G93A mice relative to their
wild-type control littermates, *p < 0.05, **p < 0.001 ***p < 0.0001 when compared with age control littermates (arbitrarily set at 1).
(G) Expression of mRNAs coding for Sln and denervation markers (Achra, Nav1.5, Hdac4, and Myogenin) in the TA of wild-type mice 3 and 15 days after
sciatic nerve axotomy. Data are expressed as the ratio between the average of values from not axotomized and axotomizedmice, *p < 0.05, **p < 0.001 when
compared with control not axotomized mice (arbitrarily set on at 1), and ##p < 0.001 between mice after 3 and 15 days from axotomy. All data are presented
as mean G SEM, unpaired Student’s t test (E) and parametric ANOVA and a Bonferroni post hoc test (F), n = 3 or 4 independent experiments.
See also Table 1.
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supply (Stanley, 2002). This drug decreases b-oxidation, thereby restoring the use of glucose as fuel (Mc-
Cormack et al., 1998).
In a preliminary dose-response study, a small cohort of SOD1G93A mice and age-matched wild-type control
mice received daily intraperitoneal (i.p.) injections, for seven consecutive days, of three different doses of
RAN (25, 50, 100 mg/kg). Treatment commenced at an age that corresponds to the symptomatic stage of
the disease in SOD1G93A mice (110 days). Bioavailability of RAN in plasma was assessed by high-perfor-
mance liquid chromatography (HPLC), and results confirmed a dose-dependent increase (Table 2). RAN
concentration values were consistent with those registered in more extended pharmacokinetics and phar-
macodynamics studies reported by others (Patel and Hasumati, 2015). Analysis of grip strength and SLN
expression were used as readouts to determine the efficacy of RAN treatment. Strikingly, SOD1G93A
mice receiving 50 and 100 mg/kg of RAN showed a marked increase in muscular strength after 2 days of
treatment. This improvement was maintained throughout the 7-day treatment period (Figure S6A). Similar
results were obtained with a lower dose of RAN (25 mg/kg), which showed a significant, although delayed,
efficacy. Furthermore, in the TA muscle of SOD1G93A mice, SLN expression was reduced after 7 days of
treatment. This was most evident at a RAN dose of 50 mg/kg (Figure S6B). As such, 50 mg/kg of RAN
was selected as the most effective dose.
A second, larger cohort of SOD1G93A mice received 50 mg/kg RAN from the onset stage of disease
(90 days) through the end stage of disease. As shown in Figure 7A, RAN treatment improved hanging
grid performance in SOD1G93A mice up until the fully symptomatic stage of the disease (132 days). Howev-
er, this improvement was not sustained; hanging grid performance in RAN-treated SOD1G93A mice was
comparable with that of non-treated SOD1G93A mice by the end stage of disease (Figure 7A). Interestingly,
RAN exerted similar effects on wild-type mice (Figure S7). Despite improving hanging grid performance in
SOD1G93A mice, RAN failed to improve survival (Figure 7B) and it did not provide weight changes (data not
shown). Interestingly, RAN treatment improves glycemia and reverses glucose intolerance in murine
models of metabolic alterations without modifying body weight development (Batran et al., 2019; Ning
et al., 2011).
It is noteworthy that treatment efficacy followed the trend of expression/activation of muscle metabolic
markers. Indeed, after 30 days of treatment with RAN, SLN was markedly downregulated and CaMKII
and AMPKwere inactivated by dephosphorylation, whereas the AMPK target, ACC, was dephosphorylated
and hence reactivated (Figures 8A and 8B). Similarly, expression levels of mRNAs encoding myosin sub-
types and SERCA pumps were decreased in response to RAN (Figure 8C), whereas mRNAs encoding
Nor1 and Glut4 returned to levels similar to that observed in wild-type control mice (Figure 8C). In line
Patient Age
(years)
Sex ALS Mutation Months from
Diagnosis
Muscle (Biopsies
Were Done on
Limb Muscle
where the Disease
Began)
Patient
Information
1 47 F SOD1D90A 12 soleus dx Spinal onset
2 72 F Sporadic 42 vastus lateralis dx Spinal onset
3 50 M VCP mutation 54 vastus lateralis dx Spinal onset with IBM
(inclusion body
myositis) and Paget’s
disease
4 62 F C9ORF72 (58
repeats)
33 soleus dx Spinal onset with
progressive muscle
atrophy
5 77 F Sporadic 19 vastus lateralis dx Spinal onset
6 71 F Sporadic 14 rectus femoris dx N/A
Table 1. Demographics of Patients with ALS
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with RAN’s known mechanism of action in improving glucose metabolism, fluorometric determination of
total ATP content showed a net increase in ATP concentration in the TA from symptomatic, 120-day-old
SOD1G93A mice when compared with their wild-type control littermates (Figure 8D).
Given that progressive changes in muscle metabolic markers in SOD1G93A mice occurred alongside the
presentation of hypermetabolism, we next aimed to determine whether RAN would attenuate hyperme-
tabolism in SOD1G93A mice. Indeed, indirect calorimetry analysis showed that hypermetabolism was
partially abrogated after treatment with RAN (Figures 8E and 8F). RAN restored EE (Figure 8G) and REE
(Figure 8H) but had no effect on RER (Figure 8I). Surprisingly, the weakening of RAN effects during the
end stage of the disease was paralleled with an increase in the expression of SLN, the reactivation of CaM-
KII and AMPK, and thus ACC inactivation (Figures 8, 8J, and 8K). Overall, these results show that decreasing
EE is linked to an improvement in grip strength in SOD1G93A mice. Our data highlight the potential rele-
vance of pharmacological interventions aimed at counteracting hypermetabolism in ALS.
DISCUSSION
In this study, we detail the existence of early events responsible for the remodeling of myofiber-type
composition and defective energy metabolism in the SOD1G93A mouse model of ALS. Our observations
are in agreement with previous work demonstrating a shift in fast-to-slow muscle fiber type composition
(Peggion et al., 2017), as well as aberrant mitochondrial metabolism (Salvatori et al., 2017) and alterations
in muscle glucose metabolism in response to muscle-restricted overexpression of SOD1G93A (Dobrowolny
et al., 2008, 2018). Moreover, in line with the derangement in whole-body EE that we identified in symptom-
atic SOD1G93A mice, hypermetabolism has been described in many patients with ALS (Bouteloup et al.,
2009; Desport et al., 2005; Funalot et al., 2009; Je´sus et al., 2018; Steyn et al., 2018) and often associated
with dyslipidemia (Dupuis et al., 2008). Notably, prognosis is less favorable in hypermetabolic patients
(Steyn et al., 2018), whereas dyslipidemia/hyperlipidemia may confer protection and increase survival (Du-
puis et al., 2008).
Given that skeletal muscle is a major determinant of whole-body energy metabolism (Zurlo et al.,
1990), we focused our investigation on the contribution of skeletal muscle to SOD1G93A metabolic
dysfunction. Indeed, we found some prodromal molecular signatures of oxidative metabolism at
55 days of age, including an initial increase in NADH-TR and SDH activities and an increase in mito-
chondrial mass in fast-twitch glycolytic muscles. Thus, we identified a fast-to-slow skeletal muscle fiber
transition in the early presymptomatic stage; this pathological rearrangement of muscle phenotype
might partially account for the marked increase of fatty acid b-oxidation observed before disease
onset. However, according to previous evidence (Doshi et al., 2017), hypermetabolism occurs in
SOD1 G93A mice only at a symptomatic stage of the disease, whereas it is undetectable at
55 days of age. It should be considered that, around 55 days of postnatal life, the skeletal muscle
of SOD1 G93A mice are not yet fully oxidative.
Skeletal muscle is a dynamic tissue that is highly adaptable to environmental changes and to alter-
ations in energy need. Physical exercise is a key modulator of muscle plasticity, as enduring contractile
activity, it is a powerful stimulus for enhancing mitochondrial biogenesis (Hood, 2009). This condition
upregulates mitochondrial enzymes involved in fatty acid b-oxidation (Lundsgaard et al., 2018) to pro-
mote myofiber switching from fast (glycolytic) to slow (oxidative) fiber types (Flu¨ck, 2006). In this view,
the muscle alterations that we have observed in SOD1G93A mice appear to mimic a state of long-last-
ing endurance exercise. Indeed, Palamiuc et al. (2015) have previously reported increased endurance
capacity in SOD1G86R mice at an advanced phase of disease. Although it remains unknown as to why
RAN Dose (mg/kg) WT (mM) SOD1G93A (mM)
25 0.63G 0.16 0.79G 0.11
50 1.22G 0.20 1.30G 0.18
100 3.33G 0.21 2.87G 0.17
Table 2. HPLC Determination of Ranolazine (RAN) Plasma Concentrations 12 h after i.p. Administration of
Ranolazine at 25, 50, or 100 mg/kg
Data are expressed as meanG SD, n = 5 per group.
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there is a shift in muscle fiber type, and enhanced fatty acid utilization in the absence of environ-
mental pressure and/or physical exercise in SOD1G93A mice, this exercise-mimetic phenotype may
be associated with aberrant energy needs that may be associated with early mitochondrial dysfunction
and/or SLN overexpression.
Mitochondrial Dysfunction
In light of the critical role that mitochondria play in muscle metabolism and plasticity, it is conceivable that
early alterations in muscle mitochondria might contribute to altered energy homeostasis in ALS. In agree-
ment with this hypothesis, we report mitochondrial impairments in skeletal muscle in early presymptomatic
SOD1G93A mice, which occur prior to the presentation of motor symptoms. Recently, an association be-
tween myopathy and defective mitochondrial function has been described in a different ALS mouse model
Figure 7. Ranolazine Improves Locomotor Abilities but Does Not Affect Survival
(A) Locomotor abilities of SOD1G93A mice receiving daily intraperitoneal injections of Ranolazine 50 mg/kg (SOD1G93A
RAN) or physiological solution (SOD1G93A) evaluated by hanging grid test at the indicated days. Performance was
evaluated from 90 days of age (start of treatment) to the end stage of disease. Data are presented as meanG SEM, *p <
0.05 **p < 0.001 ***p < 0.0001 when compared with age-matched SOD1G93A untreated mice, and #p < 0.05 ##p < 0.01
###p < 0.0001 when compared with SOD1G93A mice at the beginning of treatment. (n = 12 SOD1G93A, n = 12 SOD1G93A +
RAN).
(B) Kaplan-Meier survival curve of SOD1G93A mice and their wild-type control littermates (WT) receiving daily
intraperitoneal injections of Ranolazine 50 mg/kg (SOD1G93A RAN andWT RAN) or physiological solution (SOD1G93A and
WT). p Values were obtained using parametric two-way ANOVA with Bonferroni post hoc test (A) or one-way ANOVA with
Bonferroni post hoc test (B).
Also Figure S7.
ll
OPEN ACCESS
iScience 23, 101087, May 22, 2020 13
iScience
Article
ll
OPEN ACCESS
14 iScience 23, 101087, May 22, 2020
iScience
Article
(Genin et al., 2019), thus underlining the importance of muscle bioenergetics in neuron motor disease. In
line with premature atrophy and loss of function of fast-twitch fibers (Hegedus et al., 2008; Palamiuc et al.,
2015; Peggion et al., 2017), we detected early mitochondrial metabolic alterations in glycolytic EDL, TA,
and GNM but not in oxidative soleus. Interestingly, skeletal muscle satellite cells isolated from early pre-
symptomatic SOD1G93A mice also exhibited defective bioenergetic profiles. The drop in energy produc-
tion in these skeletal muscle stem cells and their inability to respond to metabolic changes might affect
muscle regeneration in response to denervation as previously described in ALS pathology (Tsitkanou
et al., 2016; Yin et al., 2013).
We found an early impairment of Complex I activity in skeletal muscle of SOD1G93A mice. An impairment of
Complex I activity has previously been described in muscle biopsies from patients with sporadic ALS (Wie-
demann et al., 1998). Moreover, functional alterations of the Complex I has been observed in GNM isolated
from SOD1G93A mice at 7 weeks of age (Capitanio et al., 2012). Collectively, these observations corroborate
the hypothesis that, in patients with ALS (Ghiasi et al., 2012) and in preclinical models (Salvatori et al., 2018;
Wang et al., 2016), Complex I activity is a selective target of different ALS-related proteins. Complex I can
be considered as an energy-transducing enzyme whose activity regulates cell energy request and activates
catabolic pathways following the failure of its activity (Hunter et al., 2018; Leonard et al., 2017). Accordingly,
pharmacological inhibition or a failure in Complex I activity triggers the activation of the AMPK (Hu et al.,
2017; Hunter et al., 2018). AMPK activation promotes catabolic pathways, such as lipid oxidation in skeletal
muscle (Merrill et al., 1997; O’Neill et al., 2013). This known action of AMPK is in line with the increase in lipid
oxidation and inhibition of glucose utilization that we observed here in early presymptomatic mice. In the
context of ALS, mitochondrial failure could drive an increase in the use of lipids as primary fuel substrate to
compensate for energy deficit and a decline in ATP synthesis. Subsequent to this, excess ROS generation
as a result of excessivemitochondrial lipid oxidationmay further aggravatemitochondrial dysfunction (Qui-
jano et al., 2016; Rosca et al., 2012).
SLN Overexpression
SLN is a micropeptide inhibitor of SERCA activity that uncouples Ca2+ transport from ATP hydrolysis (Bal
et al., 2012; Smith et al., 2002). Thus, SLN has a critical role in determining metabolic rate, EE, and muscle-
derived thermogenesis (Bal et al., 2012; Maurya and Periasamy, 2015; Maurya et al., 2018). Notably, selec-
tive SLN overexpression in fast-twitch glycolytic muscle has been shown to reprogram mitochondria and
induce an oxidative phenotype (Maurya et al., 2018). The expression of SLN is tightly regulated during
development, and in rodents, its expression is detectable in skeletal muscle during late embryonic
Figure 8. Chronic Ranolazine (RAN) Administration Restores Metabolic Homeostasis
Mid-term evaluation (120 days) of SOD1G93A mice receiving daily RAN (50 mg/kg i.p.) from 90 days of age.
(A) Western blot analysis of SLN, pCaMKII, CaMKII, pAMPK, AMPK, pACC, and ACC in the tibialis anterior (TA) of SOD1G93A mice (+) and wild-type control
littermates () receiving daily RAN (+) or vehicle () at 120 days of age. GAPDH was used as loading control.
(B) Densitometric analysis of data obtained in (A). Data are presented as meanG SEM, *p < 0.05, **p < 0.001 when compared with wild-type untreated mice
(arbitrarily set on at 1) and #p < 0.05 ##p < 0.001 when compared with SOD1G93A untreated mice (n = 6 independent experiments), parametric one-way
ANOVA and a Bonferroni post hoc test.
(C) Expression of mRNAs coding for Nor1, Glut4, Serca1, Serca2a, Serca2b, MyHCI, MyHCIIa, MyHCIIx, MyHCIIb in the TA of SOD1G93A mice and wild-type
control littermates treated with RAN (SOD1G93A, RAN andWT RAN) or not treated with RAN (SOD1G93A andWT) at 120 days of age (n = 4 for each genotype/
treatment). Data are presented as mean G SEM, **p < 0.001 when compared with wild-type untreated mice (arbitrarily set on at 1) and #p < 0.05 when
compared with SOD1G93A untreated mice (n = 6 independent experiments), parametric one-way ANOVA and a Bonferroni post hoc test.
(D) Fluorometric measurement of total ATP in the TA of SOD1G93A mice and wild-type control littermates receiving daily RAN (+) or vehicle () at 120 days of
age. Data were analyzed by one-way ANOVA with multiple comparisons using Dunnet’s t test and Tukey’s HSD (Honestly Significantly Different) post hoc
test. Data presented asmeanG SEM, ***p < 0.0001 when compared withWT untreatedmice and ##p < 0.001 when compared with SOD1G93A untreatedmice
(n = 4 independent experiments).
(E) Energy expenditure profile (EE) of WT and SOD1G93A treated with RAN or vehicle at 120 days of age. Black bar indicates the dark cycle period.
(F–H) (F) Percentage of increase in EE between 55 and 120days of age, and effects of RAN treatment (initiation of treatment marked with an arrow) from day
90 onward. Mean of (G) EE and (H) Resting EE (REE) obtained from WT and SOD1G93A mice in (E). Data are presented as meanG SEM, ***p < 0.0001 when
compared with WT mice; ###p < 0.0001 when compared with SOD1G93A mice (at least n = 4 animals), two-way ANOVA with Tukey post hoc test.
(I–K) (I) Respiratory exchange ratio (RER) demonstrating the extent of lipid versus carbohydrate oxidation. Data are presented as meanG SEM, ***p < 0.0001
when compared with WT mice; (at least n = 4 animals), two-way ANOVA with Tukey post hoc test. Long-term evaluation (150 days) of RAN treatment started
at 90 days of age: (J) western blot analysis of SLN, pCaMKII, CaMKII, pAMPK, AMPK, pACC, and ACC in the TA of SOD1G93A (+) and wild-type () RAN-
treated (+) or untreated () mice. GAPDH was used as loading control. (K) Densitometric analysis of data in (I). Data are presented as mean G SEM,
**p < 0.001 when compared with WT untreated mice (arbitrarily set on at 1) and #p < 0.05 when compared with SOD1G93A untreated (n = 6 independent
experiments), parametric one-way ANOVA and a Bonferroni post hoc test.
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development and early neonatal life (Babu et al., 2007). Accordingly, in control mice SLN expression was
downregulated in glycolytic muscle by postnatal day 15, whereas its expression was highly upregulated
in the same muscle during the entire life course of SOD1G93A mice. More interestingly, we found marked
SLN overexpression in muscle biopsies from patients affected by genetic and sporadic forms of ALS.
Although SLN has already been viewed as a feasible prognostic or early diagnostic biomarker in ALS, its
upregulation has been associated with disease-specific denervation (Calvo et al., 2012) rather than specific
metabolic signatures. In contrast to this, our results indicate that SLN is overexpressed before the upregu-
lation of any denervation markers. Although our data do not pinpoint SLN upregulation as being the pri-
mary ‘‘source’’ of hypermetabolism in ALS, early mitochondrial failure and energy deficit could underlie
SLN overexpression and activate compensatory oxidative metabolism. Indeed, SLN plays a central role
in the adaptive mechanisms that couple increased energy request (e.g., diet-induced obesity), cold accli-
matization, and exercise with mitochondrial ATP and energy production (Maurya et al., 2018). Thus, the in-
crease of SLN expression in ALS might represent a classical adaptation to increased energy demand, lead-
ing to a shift in substrate utilization, mitochondrial biogenesis, and oxidative metabolism in glycolytic
muscle.
RAN Treatment
To determine whether decreasing energy demand and re-balancing substrate utilization might be of
benefit in ALS, we aimed to assess the potential therapeutic role of RAN, an FDA-approved fatty acid
oxidation inhibitor that is used for the management of cardiac dysfunction (Bhandari and Subramanian,
2007; Stanley, 2002). We demonstrate that chronic RAN treatment in SOD1G93A mice significantly improves
motor function in SOD1G93A by slowing the decline in muscle strength over a 6-week treatment period.
Moreover, during mid-term treatment evaluation (120 days of age), we found that RAN attenuated exces-
sive whole-body EE in SOD1G93A mice, and although it did not offset increased fatty acid b-oxidation, RAN
treatment improved energy metabolism by increasing muscle ATP content.
Interestingly, we found that, by the end stage of disease (at 150 days), RAN had lost its efficacy and there
was a re-emergence of hypermetabolism. It should be noted that, in patients with stable angina pectoris,
the recommended posology includes the escalation of drug dosage during therapy (www.ema.europa.eu/
ema/index.jsp?curl=pages/medicines/human/medicines/000805/human_med_001009.
jsp&mid=WC0b01ac058001d124). This suggests that the re-emergence of pathology at the end stage of
disease in SOD1G93A mice may be attributed to the loss of RAN efficacy rather than disease exacerbation.
Of interest, RAN also acts as an inhibitor of late inward sodium currents (IpNa) during cardiac repolarization
(Belardinelli et al., 2013). Hence, we cannot rule out that sodium channel facilitation of membrane repolar-
ization might decrease cell energy demand to compensate for mitochondrial failure in skeletal muscle and
neurons of SOD1G93A mice.
Conclusions
Our study provides compelling evidence to demonstrate specific metabolic dysfunction andmitochondrial
failure as early pathophysiological events in ALS. Here, we may consider that a slight drop in ATP produc-
tion via mitochondrial impairment or SLN overexpression may become pathologically relevant when en-
ergy demand increases as a result of lifestyle changes or during aging. In this scenario, a timely pharmaco-
logical intervention impinging on hypermetabolism may be a promising therapeutic option to improve
quality of life.
Limitations of the Study
In this study we use an FDA-approved drug, Ranolazine, to counteract hypermetabolism in an ALS mouse
model. In our hands, Ranolazine ameliorates locomotor symptoms of fully symptomatic ALS mice, but its
effect is temporary. In this regard, RAN does not improve life span in SOD1G93A mice. Given that we
have observed temporary restoration and recovery of metabolic indicators, the loss of effectiveness of Ra-
nolazine requires further investigation through extended pharmacokinetics and pharmacodynamics
studies. From our study, we provide proof of concept that hypermetabolism appears to be considered a
viable therapeutic target in ALS. As such, alternate drugs that are known to modulate metabolism should
also be considered.
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METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2020.101087.
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Figure S1 
A 
B 
Figure S1. Quantification of muscle oxidative markers, Related to Figure 2. (A-B) Percentages of the dark areas (Blue 
for NADH-Tr activity and Purple for SDH activity, respectively) measured using ImageJ and normalized against total area. 
(C) Percentages of the red areas (ATBP fluorescent signal) measured using ImageJ and normalized against total area. 
Calculations were performed on tibialis anterior (TA) cryosections (3 for each mouse) from 3 to 4 different mice at each 
age. Data presented as means ± SEM, **P<0,001, ***P<0,0001 with respect to wild-type control littermates at the same 
age, unpaired Student’s t tes. 
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Figure S2. The mass of mitochondria increases during disease course, Related to Figure 2. Mitochondrial amount 
was determined at 55, 90, 120 and 150 days of age by assessing: (A) The ratio between ug of purified mitochondria and 
mg of tissue used for purification; tibialis anterior (TA), gastrocnemius (GNM), extensor digitorum longus (EDL) and 
soleus. Data are reported as percentage, with 100% being assigned to values obtained from age-matched wild-type 
control mice (WT), n = 4 independent experiments. (B) Western blot analysis of cytosolic (CYTO), mitochondrial (MITO) 
and nuclear (NUC) subcellular fractions obtained from the TA of WT mice from 55 to 150 days of age. Fractions were 
verified for the presence of specific markers using antibodies against GADPH for the cytosolic fraction, VDAC for the 
mitochondrial fraction and HDAC1 for the nuclear fraction. A representative immunoblot is shown. (C) RT‐qPCR 
quantification of ND3, ND5 and COX3 genes encoded by mitochondrial DNA in the TA, GNM, EDL and soleus muscle. 
Genomic DNA was used as internal standard and values of age-matched wild-type control mice was arbitrary set at 1. 
Data are presented as mean ± SEM, *P<0,05, **P<0,001, ***P<0,0001, unpaired Student’s t test, n=4 different mice for 
each age.  
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Figure S3. Mitochondrial bioenergetic failure occurs in skeletal muscle of early presymptomatic SOD1 G93A mice, 
Related to Figure 3. (A) Coupling assay on isolated mitochondria purified from different tissues of SOD1G93A mice at the 
indicated ages. Mitochondrial respiration stages are reported: basal respiration (State 2), maximally coupled respiration (State 
3), respiration due to proton leak (State 4o) and maximal uncoupled respiration (State 3u). Data are expressed as % of Oxygen 
Consumption Rate (OCR) and 100% was arbitrarily assigned to values obtained from age-matched wild-type mice. *P<0,05, 
**P<0,001, ***P<0,0001, unpaired Student’s t test. (B) Representative Coupling Assay profiles performed on mitochondria 
isolated from the indicated tissues of 55 day old SOD1G93A  mice and their wild-type control littermates. The injection of ADP, 
Oligomycin, FCCP and Antimycin A (Ant. A) are indicated with arrows. (C) Blue Native Gel mitochondrial extracts isolated from 
the TA of WT (-) and SOD1G93A (+) mice at the indicated ages. A representative gel is shown (n=3 experiments).  
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Figure S4. Alterations in metabolic targets occur early in the gastrocnemius of SOD1G93A mice, Related to 
Figure 5.  Western blot analysis of pAMPK, AMPK, pACC, ACC and CPT1 in the gastrocnemius (GMN) of SOD1G93A 
(+) and wild type mice (-) from 55 days of age to end-stage (150 days) of disease. GAPDH was used  as loading control 
(left panel). Densitometric analysis of pAMPK/AMPK and pACC/ACC ratios, and CPT1 expression (right panel).  Data 
are presented as mean ± SEM, *P<0,05, **P<0,001 when compared with wild-type mice at the same age (arbitrarily set 
at 1), n = 4 independent experiments, unpaired Student’s t test. 
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Figure S5. Expression of other SERCA regulating micropeptides, Related to Figure 6. (A) Expression of mRNAs 
coding for phospholamban (PLN) and myoregulin (MLN) in tibialis anterior of SOD1G93A mice. RT-qPCR analysis was 
performed at different stages of disease in SOD1G93A mice and their wild-type control littermates. (B) PGC1α 
expression in skeletal muscle of SOD1G93A mice. PGC1α protein expression in tibialis anterior (TA) of SOD1G93A (+) and 
wild type mice (-) at the indicated ages (left panel). β-Actin was used as loading control. Densitometric analysis of data 
(right panel), presented as mean ± SEM, *P<0,05, **P<0,001, when compared with wild-type mice at the same age 
(arbitrarily set on at 1), n = 4 independent experiments, unpaired Student’s t test. (C) Expression of mRNAs coding for 
Serca1, Serca2a, Serca2b in the TA of SOD1G93A mice. RT-qPCR analysis was performed at different stages of 
disease in SOD1G93A mice and their wild-type control littermates (at least n=3 for each stage). Results in A and C (at 
least n=3 for each stage) are expressed as the ratio between the average of values from wild-type control and 
transgenic mice, normalized to the average values of TATA box housekeeping gene. Data are presented as mean ± 
SEM when compared with control littermates at the same age (arbitrarily set on at 1), unpaired Student’s t test. 
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Figure S6. Dose response study of Ranolazine treatment, Related to 
Figure 7. (A) Locomotor abilities of SOD1G93A mice receiving daily 
intraperitoneal injection of different doses of Ranolazine (RAN) (25, 50 
and 100 mg/kg) or physiological solution (untreated) for seven days (from 
110 to 117 days of age) evaluated by hanging grid test at the indicated 
days. Performance at day 0 of treatment was considered as 100% and 
performance, at days 2, 5 and 7, were considered relative to time 0. 
*P<0,05, **P<0,001 when compared with untreated SOD1G93A and 
#P<0,05, ##P<0,001 when compared with SOD1G93A performance at the 
beginning of treatment. (B) Western blot analysis of Sarcolipin (SLN) in 
the tibialis anterior (TA) of SOD1G93A receiving daily intraperitoneal 
injection of RAN 25 mg/kg (25), 50 mg/kg (50), 100 mg/kg (100) or 
physiological solution (NT) for seven days (left panel). GAPDH antibody 
was used as loading control. Densitometric analysis of data (right panel). 
*P<0,05, **P<0,001 when compared with untreated mice (arbitrarily set at 
1). Data are presented as mean ± SEM of n = 6 independent 
experiments, parametric two-way ANOVA with Bonferroni post hoc test 
(A) and one-way ANOVA with Bonferroni post hoc test (A). 
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Figure S7. Ranolazine (RAN) treatment effect in wild-type (WT) mice, Related to Figure 7. Locomotor abilities of 
WT mice receiving daily intraperitoneal injection of Ranolazine 50 mg/kg (WT RAN) or physiological solution (WT) 
evaluated by hanging grid test at the indicated days. Performance was evaluated from 90 days of age (start of 
treatment) to an age that equates to the end-stage of disease for SOD1G93A mice. Data are presented as mean ± SEM, 
*P<0,05 **P<0,001 when compared with age-matched WT untreated mice and #P<0,05 ##P<0,01 when compared with 
WT mice at the beginning of treatment, n=11 WT, n = 11 WT RAN, parametric two-way ANOVA with Bonferroni post 
hoc test. 
METHODS 
Antibodies 
The antibodies used in this study were: AMPKα rabbit polyclonal (Cell Signaling, Cat#2532 
WB:1:1000), Phospho-AMPKα (Thr172) (40H9) rabbit monoclonal (Cell Signaling, 
Cat#2535 WB:1:1000), Acetyl-CoA Carboxylase (c83b10) rabbit monoclonal (Cell 
Signaling, Cat#3676 WB:1:1000), Phospho-Acetyl-CoA Carboxylase (Ser79) rabbit 
polyclonal (Cell Signaling, Cat#3661 WB:1:1000), anti-CPT1A (8F6AE9) mouse 
monoclonal (Abcam 128568  WB:1:1000), anti-Sarcolipin rabbit polyclonal (Millipore 
Cat#ABT13 WB 1:1000), CaMKIIα (A-1) mouse monoclonal (Santa Cruz Biotechnology 
Inc,. Cat# sc-13141 WB 1:1000), Phospho-CaMKIIα (22B1) mouse monoclonal (Santa 
Cruz Biotechnology Inc., Cat# sc-32289 WB 1:1000), PGC1alpha (H-300) Rabbit 
polyclonal (Santa Cruz Biotechnology Inc., Cat# sc-13067 WB 1:1000), anti-Laminin rabbit 
polyclonal (Cat#L9393, Sigma, IF 1:400), Anti- ATPB (3D5) mouse monoclonal  (Abcam 
Cat#ab14730 IF 1:400), anti-­‐HDAC1 rabbit polyclonal (Santa Cruz Biotechnology Inc., 
Cat# sc-­‐7872, RRID:AB_2279709, WB 1 : 1000), anti-­‐VDAC mouse monoclonal (Santa 
Cruz Biotechnology Inc., Cat# sc-­‐8829, RRID:AB_2214801, WB 1 : 5000), anti-GAPDH 
mouse monoclonal (Santa Cruz Biotechnology Inc., Cat# sc-166545, RRID:AB_2107299 
WB 1:5000), anti-β-Actin (Santa Cruz Biotechnology Inc., Cat# sc-47778, WB 1:5000). 
Anti-rabbit (Cat# 1706515, WB: 1:1000) and anti-mouse (Cat# 1706516, WB: 1:1000) IgG 
peroxidase-conjugated secondary antibodies were from Bio-Rad Laboratories, Hercules, 
CA, USA and Alexa Fluor 488 (Invitrogen, Cat# A11017, 1: 300) anti-rabbit goat antibodies 
and Cy3 anti-mouse antibody from Jackson Immuno-Research Laboratories, West Grove, 
PA, USA, Cat# 65119, 1: 300).  
 
Animals  
All animal procedures were carried out in accordance with the European Guidelines for the 
use of animals in research (2010/63/EU) and the requirements of Italian laws (D.L. 
26/2014). All procedures were approved by the Animal welfare office, Department of 
Public Health and Veterinary, Nutrition and Food Safety, General Management of Animal 
Care and Veterinary Drugs of the Italian Ministry of Health (protocol number 
931/2017/PR). Animals were kept in a virus/antigen-free facility with a light/dark cycle of 12 
h at constant temperature and humidity. Food and water were provided ad libitum.  
SOD1G93A mice (B6.Cg-Tg(SOD1 G93A)1Gur/J) were obtained from The Jackson 
Laboratory (Bar Harbor, ME, USA) and  bred in our animal facility. Transgenic hemizygous 
SOD1G93A males were crossbred with C57BL/6 females and transgenic progeny were 
genotyped by PCR. Disease onset was evaluated by hanging grid test; tests were 
conducted once per week starting at 55 days of age. The final measurement for each 
mouse was determined by calculating the mean of three different hanging grid test trials on 
each given day. A performance baseline of 100% was assigned to the first mean 
performance for each mouse at 55 days of age. Age of symptom onset was classified as 
being the time at which mouse performance deteriorated by 20% from the baseline. In our 
animal house, and using this approach, disease onset in male mice was classified as 
being 91.7 ± 2.9 days, and survival was 168.7 ± 1.9 days.  
To follow disease progression, behavioural scores and body weight were monitored 
starting at 55 days according to Apolloni et al. (Apolloni et al., 2019). In brief, we assigned 
the following age (in days) to the following disease stages: 55 days as “early 
presymptomatic”, 70 days as “presymptomatic”, 90 days as “symptoms onset”, 120 days 
as “symptomatic”, 150 days as “end stage”. Mice were anaesthetized with Rompum 
(xylazine, 20 mg/ml, 0.5 ml/kg Bayer, Milan, Italy) plus Zoletil (tiletamine and zolazepam, 
100 mg/ml, 0.5 ml/kg; Virbac, Milan, Italy), and then sacrificed for tissue dissection. 
 
Energy metabolism by indirect calorimetry 
Total Energy Expenditure (EE), Resting Energy Expenditure (REE) and Respiratory 
Exchange Ratio (RER) were measured using an indirect calorimeter system (TSE 
PhenoMaster/LabMaster System, Germany) with a constant air flow of 0.35 L/min. Mice 
were adapted for 12 hours to the metabolic chamber, and parameters were measured at 
20 minute intervals for each mouse, starting at 7:00 PM and ending automatically after 48h 
or 72h (12h dark-light phase comparison). Room temperature was kept constant (22˚±1˚C) 
and locomotor activity was assessed in parallel to discriminate between EE and REE. REE 
was analyzed by considering each animal’s resting conditions, which was defined as an 
activity count between 0 and 3. RER was calculated as: RER = volume of CO2 
produced/volume of O2 consumed (an index of substrate utilization). Mice were assessed 
under standard nutritional conditions (i.e., standard diet-fed) and food intake was 
continuously monitored (Giacovazzo et al., 2018). 
 
Glucose tolerance test (GTT) 
GTT was performed in SOD1G93A and WT mice at 55 days, 90 days and 120 days of age. 
Blood glucose was measured in tail tip blood samples using a Multicare Test Strip 
apparatus (Biochemical Systems International, Italy). Plasma glucose was assessed at 0, 
20’, 40’ and 60 min after i.p. glucose administration (2gr/kg), which was administered 
following an overnight fast (16h). The area under the curve was calculated using the 
trapezoidal rule. 
 
RNAseq 
Total RNA from the tibialis anterior (TA) muscles of 90 day old SOD1G93A mice and their 
wild-type control littermates was extracted using TRI Reagent (Sigma) following the 
manufacturer’s protocol. RNA was shipped to the sequencing IGA of Udine 
(https://appliedgenomics.org/it/). The libraries for sequencing were prepared using NuGEN 
Ovation System V2 RNA–Seq. For each biological sample two independent experiments 
were carried out for the isolation of RNA.  
Read quality control was asserted through FastQC 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/), and quality/adapter trimming 
was carried out using Trim 
Galore   (https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/), which itself is 
a wrapper for cutadapt. Subsequently, reads were pseudo aligned to transcriptome 
GRCm38 (mm10) using Kallisto version 0.43.1. Count tables were generated in R using 
the package tximport together with DESeq2. Differential expression of genes was 
conducted using DESeq2 with default options. Genes were considered differentially 
expressed if the adjusted P-value was<0.05. 
RNA-seq data of this study have been deposited in the Sequence Read Archive (SRA) 
under the accession code: PRJNA623256 
(https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA623256) 
 
 
Histochemistry and Immunofluorescence 
For histochemistry and immunofluorescence analysis, 10  µm muscle cryosections were 
obtained from SOD1G93A mice and their wild-type control littermates at different stages of the 
disease.  
For NADH-tetrazolium reductase activity staining (NADH-TR), muscle cryosections 
were incubated for 15 min with a solution containing NADH and nitrotetra-zolium blue (# 
N8129 and #N6876, Sigma-Aldrich) in Tris-HCl (pH 7.4) at 37°C (Madaro et al., 
2013).  Enzymatic staining for succinate dehydrogenase (SDH) activity was performed 
according to Molinari et al. (Molinari et al., 2017). Briefly, TA cross-sections were 
incubated for 20′ at 37 °C in PBS containing 1 mg/ml of nitrotetrazolium blue chloride 
(Sigma-Aldrich, St. Louis, MO, USA) and 27 mg/ml of Na-succinate. After staining, 
sections were fixed with 4% PFA and images from three serial sections per animal were 
acquired using an Olympus BX53 (Olympus). Images were processed using Image 
analysis IAS software (Delta Sistemi). 
For immunofluorescence, cryosections were fixed in 4% PFA for 10  min, 
permeabilized with 0.25% Triton for 15  min at room temperature, and blocked for 1  h with a 
solution containing 4% BSA in PBS. Samples were then incubated for 2 h at room 
temperature with primary antibodies followed by Alexa 488- or Cy5- conjugated secondary 
antibodies. After rinsing in PBS, cryosections were counterstained with 1  µg/ml Hoechst 
33342 (Sigma-Aldrich) in PBS and visualized with a Zeiss LSM 800 Confocal Laser 
Scanning Microscope. Fluorescence images were processed using ZEN 2.6 (Blue Edition) 
(Carl Zeiss, Milan, Italy) and Adobe Photoshop software (Adobe, San Jose, CA, USA). 
Densitometric analyses were performed using ImageJ (U. S. National Institutes of Health, 
Bethesda, Maryland, USA, https://imagej.nih.gov/ij/, 1997-2016). 
  
 
Isolation, quantification and bioenergetic analysis of isolated mitochondria 
Mitochondria were isolated from the TA, gastrocnemius (GNM), extensor digitorum longus 
(EDL), soleus and spinal cord of SOD1G93A mice and their wild-type control littermates, at 
different stages of the disease. According to Salvatori et al., tissues were homogenized in 
210 mM mannitol, 70 mM sucrose, 1 mM EDTA and 10 mM HEPES KOH (pH 7.5) through 
a Glass/Teflon Potter Elvehjem homogenizer (Salvatori et al., 2017, 2018). The total 
concentration of mitochondria was determined using a Bradford assay (Bio-Rad, Cat# 
5000006) and the obtained quantity was normalized to the weight of the starting material 
to determine µg of mitochondria per mg of tissue. Tissue mitochondrial content was also 
assayed by quantitative real-time PCR in which the quantity of mitochondrial DNA / 
genomic DNA was evaluated (see also below in “DNA-RNA isolation and Real Time 
PCR”). 
Isolated mitochondria were resuspended in a minimum volume of Respiration Buffer 
(250 mM Sucrose, 15 mM KCl, 1 mM EGTA, 5 mM MgCl2, 30 mM K2HPO4), loaded (4 µg 
for skeletal muscles and 12 µg for spinal cord) onto a Seahorse XFe96 microplate, and 
centrifuged for 20 minutes at 2000 x g. After centrifugation 180 µl of Respiration Buffer 
[containing substrates: pyruvate (5 mM), malate (2.5 mM), glutamate (5 mM)] were added 
to each well, and the microplate was incubated at 37°C for 8 min to equilibrate the plate 
temperature. During plate incubation, the XFe96 cartridge was loaded with drugs to a final 
concentration of:  ADP 1 mM, oligomycin 3 µM , FCCP 12 µM and Antimycin A 2 µM. 
Microplates containing mitochondria were then loaded into Seahorse XFe96 Extracellular 
Flux Analyzer (Seahorse Bioscience-Agilent) and the assay was completed according to 
the protocol developed by Seahorse Agilent. Coupling assays were performed across 6 
technical replicates per plate, for 3 experiments. This assay allows for the assessment of 
electron transport chain functionality and oxidative phosphorylation flow tracing O2 
Consumption Rates (OCR) in basal conditions (mitochondrial State 2 respiration) and in 
response to the administration of ADP (maximal coupled respiration, or mitochondrial 
State 3 respiration), Oligomycin A (respiration due to proton leak, or mitochondrial State 4o 
respiration), FCCP (maximal uncoupled respiration, or mitochondrial State 3u respiration) 
and Antimycin A (inhibition of oxidative respiration). 
 
Blue Native PAGE (BN-PAGE) 
BN-PAGE was performed on mitochondria purified from the TA of SOD1G93A mice and their 
wild-type control littermates using a NativePAGE™ Sample Prep Kit (Invitrogen™, Cat # 
BN2008). Specifically, 20ug of mitochondrial protein was loaded into 4-16% gradient gels 
(Bio-Rad), electrophoresed at 150 V for 120 minutes, and stained with 10% acetic acid, 
25% isopropanol and Coomassie blue G250. The apparent molecular weight was 
determined using NativeMark™ Unstained Protein Standard molecular weight markers 
(Invitrogen™, Cat # LC0725). 
 
Total ATP evaluation 
Total ATP concentration was measured in the TA  of SOD1G93A mice and their wild-type 
control littermates using an ATP Colorimetric/Fluorometric Assay Kit (BioVision, Inc., 
Milpitas, CA). Samples were loaded in 96-well microtiter plates and the fluorometric 
measurement of tissue ATP concentration was determined at Ex / Em = 535/587 nm using 
a plate reader (Perkin Elmer 1420 Multilabel Counter Victor3V).  
 
Biochemical assays 
The activity of respiratory chain complexes (Complex I, II/III, IV) was evaluated in isolated 
mitochondria obtained from ALS mice and their wild-type control littermates at different 
stages of the disease according to Salvatori et al. (Salvatori et al., 2018), with some 
modifications. Briefly, tissues were sonicated (UP200S Ultrasound Technology, Hielscher, 
Teltow, Germany, 20% Amplitude, 0.5 cycles for 30 s) and the reduction or oxidation of 
specific substrates was recorded by spectrophotometric measures. Complex I activity was 
performed by monitoring the oxidation of NADH at 340 nm at 30°C in a 1 mL quartz 
cuvette containing 25 mM potassium phosphate pH 7.4, 5 mM MgCl2, 5 mg/mL bovine 
serum albumin, 1 mg/mL Antimycin A, 65 µM decylubiquinone, 130 µM NADH and 80 µg 
of total mitochondrial protein. Complex II/III activity was performed by monitoring the 
reduction of ferricytochrome c at 540 nm in a 1-ml cuvette at 30°C containing 20mM 
succinate, 0.5 mM EDTA, 2 mM KCN, and 25 µg total mitochondria protein. Complex IV 
activity was assayed following the oxidation of ferricytochrome c at 540 nm in a 1 ml 
cuvette at 30°C.  Spectrophotometric determination of citrate synthase activity was 
measured according to Ferri et al. (Ferri et al., 2006) and values were used as standard 
internal controls. 
 
Bioenergetic analysis of isolated skeletal muscle satellite cells 
Skeletal muscle satellite cells were isolated from 55 day old SOD1G93A mice and age-
matched wild-type controls through magnetic beads-associated cells sorting according to 
Reggio et al. (Reggio et al., 2020). Mice were euthanized via cervical dislocation, and 
hindlimbs were carefully skinned, dissected and placed in HBSS supplemented with 2% 
BSA and 1% Pen/Strep (SupHBSS). Muscles were dissociated from bones in a sterile 
hood and minced into small pieces. Minced tissue was separated at 700 x g for 10 min at 
4°C and digested with 2 µg/µl collagenase A (Roche), 2.4 U/ml dispase II (Roche), and 10 
µg/ml DNase I (Roche) in DPBS w/calcium and magnesium, for 1h under agitation in a 
water bath at 37°C. Digested tissue was separated at 700 x g for 10 min at 4°C, 
resuspended in SupHBSS and sequentially filtered through 100 µm, 70 µm and 40 µm 
nylon cell strainers previously hydrated with SupHBSS. After each filtration step, the cell 
suspension was separated and resuspended. Red blood cells were lysed with RBC buffer 
(ChemCruz) between the 70 µm and 40 µm filtration steps by incubating the cell pellet in 1 
ml of 1X RBC for 2.5 min on ice, and inactivated with SupHBSS. The final cell suspension 
was separated and resuspended in magnetic beads buffer (MBB) consisting of DPBS w/o 
calcium and magnesium supplemented with 0.5% BSA and 2 mM EDTA, and filtered 
through 30 µm cell strainer. Cell sorting was carried out by incubating the cell pellet with 
anti-CD45 and anti-CD31 antibody to eliminate immune/hematopoietic and endothelial 
cells. Incubation with anti-7-integrin antibody yielded the satellite cell fraction. To 
precipitate contaminating fibroblasts, the 7-integrin positive fraction was pre-plated for 2h 
in growth medium consisting of DMEM high-glucose Glutamax (Gibco), supplemented with 
1 mM sodium pyruvate, 1% pen/strep, 20% FBS, 10% horse serum, and 2% chicken 
embryo extract. Unattached cells were recovered and plated for proliferation in 
CytoGROW medium (Resnova) at a density of 200000 cells/100 mm dish. After 4 days of 
proliferation, cells were trypsinized and counted for analysis using a Seahorse XFe96 
Extracellular Flux Analyser (Seahorse Bioscience-Agilent, USA). Bioenergetic profiles of 
skeletal muscle satellite cells isolated from SOD1G93A mice and wild-type age-matched 
controls were performed using a Mito Stress Test Kit (Seahorse Bioscience), following the 
manufacturer’s instructions and according to Salvatori and collaborators (Salvatori et al., 
2018). 
 
Human samples and ethics statement 
Muscle biopsies from ALS patients were obtained for diagnostic purposes in the 
Department of Medical, Surgical and Neurological Sciences of the University of Siena, 
Siena, Italy. All patients signed informed consent to permit the use of their samples for 
research. Our study complies with the ethical standards established in the 1964 
Declaration of Helsinki and its later amendments. 
  
Electrophoresis and western blotting 
Protein samples were separated by SDS–polyacrylamide gel electrophoresis and 
transferred to nitrocellulose membranes (Perkin Elmer, Cat# NBA085B). Membranes were 
blocked for 1 h in Tris-buffered saline solution with 0.1% Tween-20 (TBS-T) containing 5% 
BSA, and then incubated for 2 h at room temperature or overnight at 4°C with indicated 
primary antibodies, diluted in TBS-T containing 2% BSA. After rinsing with TBS-T solution, 
membranes were incubated for 1 h with the appropriate peroxidase-conjugated secondary 
antibody diluted in TBS-T containing 1% BSA, then washed and developed using the 
enhanced chemiluminescence detection system (Roche Molecular Diagnostics, CA, USA, 
Cat# n11500694001 or BIO-RAD ClarityTM Western ECL substrate Cat# 170-5061). 
Densitometric analyses were performed using ImageJ (U. S. National Institutes of Health, 
Bethesda, Maryland, USA, https://imagej.nih.gov/ij/, 1997-2016). Protein relative 
expression values were normalized to GAPDH or β-Actin. The apparent molecular weight 
of proteins was determined by calibrating the blots with pre-stained molecular weight 
markers (Bio-Rad Laboratories, Cat# 161-0394).  
 
DNA-RNA isolation and Real Time qPCR 
Mitochondrial and genomic DNA were isolated according to Miller (Miller, 2003), whereas 
total RNA was extracted with Trizol and retro-transcribed with a SensiFASTtm cDNA 
synthesis kit  (Bioline Cat# BIO-65054). Mitochondrial DNA content and mRNA expression 
levels were determined by Real Time qPCR reactions using a Light Cycler 480 SYBR 
Green System (Roche ETC). Cp values were calculated using the ‘second derivative max’ 
algorithm of the Lightcycler software. Relative mitochondrial DNA content was normalized 
to the genomic genes TNF-alfa and Interleukin 2 (IL2), whereas mRNA relative expression 
values were normalized to the housekeeping gene TATA box binding protein. Results, 
where not specifically expressed, were reported as the ratio between the average of 
values from wild-type control mice and SOD1G93A mice, normalized to the average values of 
genomic genes or the housekeeping gene. Primers sequences are listed in Table 3.  
  
Treatment and assessment of motor function 
In order to evaluate the best effective dose of drug, 110 day old SOD1G93A transgenic mice 
and their wild-type control littermates (n=6 for each dose) were treated for seven days with 
or without Ranolazine (Selleckchem, catalog #S1425) (0 mg/kg, 25 mg/kg, 50 mg/kg, 100 
mg/kg) by daily intraperitoneal injection. Motor ability were monitored as described in 
Ferraro et al., and in detail elaborated here,  using the hanging grid test at days 0, 2, 5 and 
7 of treatment; the average value from three trials (recorded from each mouse) was 
averaged to determine the final test score (Ferraro et al., 2016). Improvements in 
performance was expressed as a percentage of the starting value obtained at day 0, which 
was designated as 100%. After seven days of treatment, animals were euthanized by 
cervical dislocation and the TA and GNM muscles were rapidly excised for subsequent 
analyses.  
The selected dose of Ranolazine (50 mg/kg) was then administered to SOD1G93A 
transgenic mice at the onset of the disease (90 days old) and wild-type age-matched 
control mice. A control group of SOD1G93A transgenic and wild-type age-matched control 
mice were treated with physiological solution. Mice were weighed and assessed by the 
hanging grid test once per week starting at beginning of treatment. The final weekly 
hanging grid score per mouse per week was determined as above. Groups of 120 day 
(n=12) and 150 day old mice (n=11/12) were sacrificed for evaluation of mid- and long- 
term treatment effects respectively. Survival was determined by noting the day at which 
animals achieved full paralysis of hind limbs and were not able to right within 30 s after 
being turned on the back. At this stage animals were sacrificed according to guidelines for 
preclinical testing (Poppe et al., 2014). In order to minimize sex related differences, we 
used male mice for both pilot and long-term treatments.  
 
HPLC analysis of plasma ranolazine concentration  
Plasma (100 ul) obtained from treated and untreated mice was added to 200 ul of 
acetonitrile, vortexed, and kept on ice for 5 min. The samples were then centrifuged for 10 
min at 19000 RCF at room temperature, and the supernatants were subsequently diluted 
in solvent A (0,3% H3PO4 ) at a 1:1 (v:v) ration. 20 ul of each sample was injected into a 
HPLC system (series 200, Perkin Elmer) equipped with a Supelcosil LC-318 column (5um 
particle size, 25 cmx4.6mm). The isocratic HPLC elution mobile phase was composed of 
solvent A and solvent B (35% acetonitrile, 0,3% H3PO4) 10:90 (v:v). The flow rate was 0.8 
ml/min and the column was maintained at room temperature. Total run time was 31 min 
and the retention time of ranolazine was 15.75 min. The UV/Vis detector was set at a 
wavelength of 223 nm. 
 
Data analysis 
Data are presented as mean ± SEM. Data were analysed using Kaplan-Meier, Student’s t-
test (two group comparison), one-way or two-way ANOVA. Post-hoc analysis was carried 
out using Bonferroni or Tukey tests. Statistical analysis was carried out using Graphpad 
Prism 5 software. 
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TABLE S1. Target genes and oligonucleotide sequences, Related to Figure 2, Figure 
5, Figure 6, Figure 8, Figure S2, Figure S5. 
Target Forward sequence Reverse sequence 
TNF-alpha 5’-CTGTGAAGGGAATGGGTGTT-3’ 3’-CCCAGCATCTTGTGTTTCTG-5’ 
IL2 5’TAGGCCACAGAATTGAAAGATCT-
3’ 
3’-
GTAGGTGGAAATTCTAGCATCATCC-5’ 
ND3 5’-CCCTTACGAGTGCGGCTTC-3’ 3’-AGTGGCAGGTTAGTTGTTTGTAGG-
5’ 
ND5 5’-AGCATTCGGAAGCATCTTTG-3’ 3’-TCGGATGTCTTGTTCGTCTG-5’ 
COX3 5’-CACTAAATCAAGCCCTACTA-3’ 3’-GAAATGGAGAATGATGTTTCA-5’ 
MyHCI 5’-TGCAGCAGTTCTTCAACCAC-3’ 3’-TCGAGGCTTCTGGAAGTTGT-5’ 
MyHCIIa 5’-AGTCCCAGGTCAACAAGCTG-3’ 3’-GCATGACCAAAGGTTTCACA-5’ 
MyHCIIx/d 5’-AGTCCCAGGTCAACAAGCTG-3’ 3’-CACATTTGGCTCATCTCTTGG-5’ 
MyHCIIb 5’-AGTCCCAGGTCAACAAGCTG-3’ 3’-TTTCTCCTGTCACCTCTCAACA-5’ 
Pgc1α 5’-GTCAACAGCAAAAGCCACAA-3’ 3’-TCTGGGGTCAGAGGAAGAGA-5’ 
Glut-4 5’-GGCATGGGTTTCCAGTATGT-3’ 3’-GCCCCTCAGTCATTCTCATG-5’ 
Nor1 5’-TACGCCACGCAGACTTATGG-3’ 3’-TGGTCAGCTTGGTGTAGTCG-5’ 
Pdk4 5’-AAAGAGGCGGTCAGTAATCC-3’ 3’-TCCTTCCACACCTTCACCACA-5’ 
Serca1 5’-CACCACCAACCAGATGTCAG-3’ 3’-TCAAGACCTCTCCCTCAGGA-5’ 
Serca2a 5’-TCTCCTTGCCTGTGATCCTC-3’ 3’-GCACCCGAACACCCTTATATT-5’ 
Serca2b 5’-AGTTGAGCCAGCAGACATTG-3’ 3’-CCAGAGAATCATGCAAAAGACA-5’ 
Phospholamban (Pln) 5’-CACGTCAGAATCTCCAGAACC-3’ 3’-GCTCTTCACAGAAGCATCACA-5’ 
Myoregulin (Mln) 5’-CAACGTTGCTAGGAGAACAC-3’ 3’-GCTCTTGCCACTCATGTTCA-5’ 
Sarcolipin (Sln) 5’-TGAGGTCCTTGGTAGCCTGA-3’ 3’-CACACCAAGGCTTGTCTTCA-5’ 
AchRα 5’-GGCTTTCACTCTCCGCTGAT-3’ 3-’TCAGCGGCGTTATTGGACTC-5’ 
AchRε 5’-CTCTGCCAGAACCTGGGTG-3’ 3’-GACAGTTCCTCTCCAGTGGC-5’ 
Nav1.5 5’-AGATGTCTCCCCCAGTAACCA-3’ 3’-CTTGGGGAGCCTGTCTCTC-5’ 
Hdac4 5’-TGTACGACGCCAAAGATGAC-3’ 3’-CGGTTCAGAAGCTGTTTTCC-5’ 
Myogenin 5’-TCAGACAGGGTCCATCCCAT-3’ 3’-GCTGACTGTGAGCATCCACT-5’ 
MuRF-1 5’-GACAGTCGCATTTCAAAGCA-3’ 3’-AACGACCTCCAGACATGGAC-5’ 
Myostatin 5’-CTGTAACCTTCCCAGGACCA-3’ 3’-TCTTTTGGGTGCGATAATCC-5’ 
Myoglobin 5’-CTGTTTAAGACTCACCCTGAGAC-
3’ 
5’-GGTGCAACCATGCTTCTTCA-3’ 
TATA box binding 
protein 
5’-CCAATGACTCCTATGACCCCTA-3’ 3’-CAGCCAAGATTCACGGTAGAT-5’ 
 
